- Home
- IPHA vs BANX Comparison
IPHA vs BANX Comparison
Compare IPHA & BANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- BANX
- Stock Information
- Founded
- IPHA 1999
- BANX 2013
- Country
- IPHA France
- BANX United States
- Employees
- IPHA N/A
- BANX N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- BANX Trusts Except Educational Religious and Charitable
- Sector
- IPHA Health Care
- BANX Finance
- Exchange
- IPHA Nasdaq
- BANX Nasdaq
- Market Cap
- IPHA 160.1M
- BANX 146.9M
- IPO Year
- IPHA 2019
- BANX N/A
- Fundamental
- Price
- IPHA $2.16
- BANX $20.66
- Analyst Decision
- IPHA Strong Buy
- BANX
- Analyst Count
- IPHA 1
- BANX 0
- Target Price
- IPHA $11.00
- BANX N/A
- AVG Volume (30 Days)
- IPHA 6.4K
- BANX 23.4K
- Earning Date
- IPHA 09-17-2025
- BANX 06-17-2025
- Dividend Yield
- IPHA N/A
- BANX 9.66%
- EPS Growth
- IPHA N/A
- BANX N/A
- EPS
- IPHA N/A
- BANX 2.35
- Revenue
- IPHA $20,831,349.00
- BANX $29,467,794.00
- Revenue This Year
- IPHA $350.96
- BANX N/A
- Revenue Next Year
- IPHA $32.92
- BANX N/A
- P/E Ratio
- IPHA N/A
- BANX $8.88
- Revenue Growth
- IPHA N/A
- BANX 2.73
- 52 Week Low
- IPHA $1.29
- BANX $17.99
- 52 Week High
- IPHA $3.51
- BANX $21.67
- Technical
- Relative Strength Index (RSI)
- IPHA 52.85
- BANX 51.90
- Support Level
- IPHA $2.04
- BANX $20.53
- Resistance Level
- IPHA $2.20
- BANX $20.82
- Average True Range (ATR)
- IPHA 0.10
- BANX 0.28
- MACD
- IPHA -0.02
- BANX 0.00
- Stochastic Oscillator
- IPHA 33.83
- BANX 43.28
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About BANX ArrowMark Financial Corp.
ArrowMark Financial Corp is a non-diversified, closed-end management investment company. Its objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds and others.